These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29633674)

  • 1. DIRECT COSTS OF TYPE 2 DIABETES: A BRAZILIAN COST-OF-ILLNESS STUDY.
    Henriques RS; Steimbach LM; Baptista DR; Lenzi L; Tonin FS; Pontarolo R; Wiens A
    Int J Technol Assess Health Care; 2018 Jan; 34(2):180-188. PubMed ID: 29633674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
    Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Duh MS; Lefebvre P
    J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.
    Bron M; Guerin A; Latremouille-Viau D; Ionescu-Ittu R; Viswanathan P; Lopez C; Wu EQ
    J Med Econ; 2014 Sep; 17(9):646-57. PubMed ID: 24959693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalization costs for heart failure in people with type 2 diabetes: cost-effectiveness of its prevention measured by a simulated preventive treatment.
    Caporale JE; Elgart J; Pfirter G; Martínez P; Viñes G; Insúa JT; Gagliardino JJ
    Value Health; 2011; 14(5 Suppl 1):S20-3. PubMed ID: 21839892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.
    Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and incremental costs from a medication adherence pilot intervention targeting low-income patients with diabetes at risk of cost-related medication nonadherence.
    Ryan JG; Fedders M; Jennings T; Vittoria I; Yanes M
    Clin Ther; 2014 Dec; 36(12):1991-2002. PubMed ID: 25282579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain.
    Mata-Cases M; Casajuana M; Franch-Nadal J; Casellas A; Castell C; Vinagre I; Mauricio D; Bolíbar B
    Eur J Health Econ; 2016 Nov; 17(8):1001-1010. PubMed ID: 26542160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Reed SD; Li Y; Leal J; Radican L; Adler AI; Alfredsson J; Buse JB; Green JB; Kaufman KD; Riefflin A; Van de Werf F; Peterson ED; Gray AM; Holman RR;
    Diabetes Obes Metab; 2018 Jul; 20(7):1732-1739. PubMed ID: 29573215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system.
    Bahia LR; Araujo DV; Schaan BD; Dib SA; Negrato CA; Leão MP; Ramos AJ; Forti AC; Gomes MB; Foss MC; Monteiro RA; Sartorelli D; Franco LJ
    Value Health; 2011; 14(5 Suppl 1):S137-40. PubMed ID: 21839888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease and Economic Burden of Hospitalizations Attributable to Diabetes Mellitus and Its Complications: A Nationwide Study in Brazil.
    Rosa MQM; Rosa RDS; Correia MG; Araujo DV; Bahia LR; Toscano CM
    Int J Environ Res Public Health; 2018 Feb; 15(2):. PubMed ID: 29419786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial.
    Chen JH; Ou HT; Lin TC; Lai EC; Kao YH
    Int J Clin Pharm; 2016 Feb; 38(1):88-95. PubMed ID: 26499503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania.
    Domeikienė A; Vaivadaitė J; Ivanauskienė R; Padaiga Ž
    Medicina (Kaunas); 2014; 50(1):54-60. PubMed ID: 25060205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States.
    Ali SN; Dang-Tan T; Valentine WJ; Hansen BB
    Adv Ther; 2020 Feb; 37(2):869-882. PubMed ID: 31925649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs for hospitalized patients with diabetes mellitus in China.
    He M; Ma J; Wang D; Yu X
    Asia Pac J Public Health; 2015 Mar; 27(2):NP925-35. PubMed ID: 22743857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
    Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
    Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.